AptarGroup, Inc. ( (ATR) ) has released its Q1 earnings. Here is a breakdown of the information AptarGroup, Inc. presented to its investors.
AptarGroup, Inc. is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies, serving various sectors including pharmaceuticals, beauty, food, and personal care. In its first quarter of 2025, AptarGroup reported a 3% decrease in sales to $887 million and a 5% decrease in net income to $79 million compared to the previous year. Despite these declines, the company achieved a 3% increase in adjusted EBITDA to $183 million, with a margin expansion of 120 basis points. The pharma segment showed growth in proprietary drug delivery systems, while the beauty and closures segments faced challenges with decreased sales. AptarGroup returned $110 million to shareholders through dividends and share repurchases. Looking ahead, AptarGroup’s management remains optimistic about continued growth across its segments, expecting positive contributions from its diverse product offerings in resilient markets such as chronic disease medications and consumer staples. The company anticipates earnings per share for the second quarter of 2025 to range between $1.56 and $1.64, supported by its robust supply chain and market position.